You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九洲藥業(603456.SH):瑞博製藥通過高新技術企業重新認定
格隆匯 01-22 15:24

格隆匯1月22日丨九洲藥業(603456.SH)公佈,公司全資子公司浙江瑞博製藥有限公司(“瑞博製藥”)於近日收到全國高新技術企業認定管理工作領導小組辦公室頒佈的《關於浙江省2019年高新技術企業備案的覆函》(國科火字[2020]32號),證書編號為GR201933000479,發證日期為2019年12月4日,高新技術企業資格有效期為三年。

此次系瑞博製藥原高新技術企業證書有效期滿後進行的重新認定,根據國家有關規定,瑞博製藥自通過高新技術企業重新認定起,連續三年(2019年至2021年)可繼續享受國家關於高新技術企業的税收優惠政策,即按15%的税率繳納企業所得税。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account